Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab

CONCLUSION: Our study shows a more favorable safety profile of s.c. versus i.v trastuzumab administration. The use of s.c. trastuzumab could be advisable in at-risk patients.PMID:33780903 | DOI:10.1016/j.breast.2021.03.004

Source: Breast - March 29, 2021 Category: Cancer & Oncology Authors: Rita De Sanctis Laura Giordano Federica D'Antonio Elisa Agostinetto Arianna Marinello Daniela Guiducci Giovanna Masci Agnese Losurdo Monica Zuradelli Rosalba Torrisi Armando Santoro Source Type: research